Project Grant R43AI145766

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,000,000 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Vast Therapeutics, Inc. to develop a nebulized nitric oxide-releasing formulation (ALX1) as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients. The project aims to enhance the product quality and stability, identify optimal dosing for nebulization in an animal model, and study the biological fate of the active...

This $2,308,174 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research to develop new antimicrobial combinations and strategies to combat the threat of drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The key products and services being delivered include: Generating novel mechanistic insights into antibiotic resistance mechanisms and bacterial...

Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,530 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Scientific Horizons Consulting LLC located in Irvine, CA. The goal of this one-year grant is to develop a novel antibiotic delivery system using cyclodextrin-based metal-organic frameworks (CD-MOFs) to improve the treatment of non-tuberculous mycobacterial (NTM) lung infections. The key innovations include high antibiotic...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,878 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Medical University of South Carolina. The purpose of this R34 clinical trial planning grant is to develop a detailed protocol and documentation to conduct a future randomized, blinded, placebo-controlled clinical trial evaluating the efficacy and safety of the antibiotic omadacycline, in combination with other...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405 to Colorado State University to develop new 3-4 drug regimens containing the spectinamide antibiotic administered via inhalation for the treatment of drug-sensitive and multidrug-resistant tuberculosis (TB). The key objectives are to: 1) manufacture and characterize larger quantities of the spectinamide dry...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $155,227 to investigate a new treatment approach for Mycobacterium abscessus (MAB) chronic lung disease. The key objectives are to generate proof-of-concept data on using a monoclonal antibody (CMTX-101) to disrupt MAB biofilms in the lungs, which can improve the effectiveness of antibiotic treatments that...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The research aims to characterize the mechanism of action of a promising antibody (S3D4) that can directly kill P. aeruginosa,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $802,798 to develop a novel class of antibiotics called Biamyxins (BMX) to target multidrug-resistant Gram-negative bacterial infections. The 5-year award supports research to identify a qualified lead development candidate and pursue an Investigational New Drug (IND) candidate that can treat infections caused by...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $600,000 in funding to Via Therapeutics, LLC, a small business in Austin, Texas, to develop an inhalable dry powder formulation of D29 mycobacteriophages for the treatment of tuberculosis (TB). The key objectives of this Phase 1 award are to: 1) Develop a stable, aerosolizable dry powder comprised of D29 phages...